Qsymia has had its market debut in the US but it is not available in Europe yet. Earlier this year, the FDA vote approving the drug (which contains phentermine and topiramate) was almost unanimous and results from clinical trials were very successful across the board, with patients losing 10% of their original body weight.
With few options left for the treatment of obesity but for invasive weight loss surgeries, this could be a very exciting drug to have on the market in Europe and all going well this will be the case very soon . The European Medicines Agency (EMA) has been talking to Vivus regarding European approval and a decision is due later this year. As we have said before, we anticipate a positive outcome and will be updating this page as soon as we have more news. We expect Qsymia to be called Qnexa in Europe.